As a partner of UNITE4TB we are happy to share this news 👇 Find out more about our role in the project: https://lnkd.in/e--9t6HK #GlobalHealth #PublicPrivatePartnership #PioneeringMedicineTogether Innovative Health Initiative (IHI) AMR Accelerator
🚀 Exciting Milestone! UNITE4TB has successfully completed participant recruitment for its DECISION trial. This pivotal Phase 2B study is set to evaluate the safety and efficacy of the novel antibiotic BTZ-043 for drug-sensitive TB. Kudos to our dedicated team and partners for their hard work and commitment to advancing TB treatment. 🌍💊 Learn more about this latest milestone and its potential impact 👉 https://lnkd.in/e3ccJdT9 #YesWeCanEndTB #SaveLives #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). AMR Accelerator, LMU Munich – Ludwig-Maximilians-Universität München, LMU Klinikum München, Michael Hoelscher, EFPIA - European Federation of Pharmaceutical Industries and Associations, German Center for Infection Research